Compare Commvault Systems Inc (CVLT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs McKesson Corporation — how do they compare? Commvault Systems Inc trades at $140.74 (market cap $5.78B), while McKesson Corporation trades at $887.52 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 18.2× Commvault Systems Inc's market cap, and McKesson Corporation pays a 0.42% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals.
| CVLT | MCK | |
|---|---|---|
Market Cap | $5.78B | $105.14B |
Sector | Technology | Health |
52-Week High | $195.41 | $995.69 |
52-Week Low | $75.18 | $659.01 |
Enterprise Value | $5.76B | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $140.52, up 0.78% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 81% gross margins, and 32.77% ROE, though valuation metrics appear elevated with P/E at 89.35. Recent news highlights positive developments including Threat Scan integration with Google and strong Q1 2027 results with 16% subscription revenue growth.
CVLT presents growth potential with 22% ARR growth and analyst consensus target of $172.40 (23% upside), but faces risks from fiduciary investigations and high valuation multiples. The stock's technical strength and fundamental execution support bullish sentiment, though investors should monitor the ongoing legal scrutiny and margin compression from 7.64% to 5.61% net margin projection.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
